[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644043":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":25,"responsibleParty":42,"collaborators":25,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":25,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":25,"overallStatus":63,"whyStopped":25,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":25},{"fullName":5,"class":6},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ACT-777991","EXPERIMENTAL","Participants will receive ACT-777991 tablets orally for 24 weeks.",[13],"Drug: ACT-777991",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo tablets orally for 24 weeks.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ACT-777991 tablets",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"ACT-777991-matching placebo tablets",[15],[30],{"name":31,"affiliation":5,"role":32},"Clinical Trials","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Clinical Trial Information USA","CONTACT","+1 856 661 37 21","idorsiaclinicaltrials@idorsia.com",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":38},"Clinical Trial Information Europe","+41 58 844 1977",{"type":43,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100644043","phase-2-a-study-to-learn-how-safe-act-777991-is-and-how-well-it-works-in-adults-with-non-segmental-vitiligo-100644043",false,"NCT07667569","A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo","A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo","Inclusion Criteria:\n\n* Clinical diagnosis of either active or stable non segmental vitiligo for at least 3 months prior to Screening and meet all the following criteria:\n\n  * F-VASI score ≥ 0.3 based on BICR at Screening.\n  * T-VASI score ≥ 5 based on investigator assessment at Screening and Randomization.\n  * Total body surface area (BSA) involvement, including the face, ≤ 50% based on investigator assessment at Screening and Randomization.\n* Participants must agree not to use therapeutic agents and procedures to treat vitiligo from Screening until Participant Last Visit.\n\nExclusion Criteria:\n\n* Clinical diagnosis of other forms of vitiligo (e.g., segmental) or other hypo- or depigmentation disorders (e.g., piebaldism, leukoderma, Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation).\n* Any autoimmune disease, except adequately treated thyroid disease.\n* History of systemic immunotherapy treatment, including JAK inhibitors, for any inflammatory disease in the 12 months prior to Randomization.\n* History of topical JAK inhibitors for any inflammatory disease in the 6 weeks prior to Screening.\n* Use of laser or light-based treatment (phototherapy), including tanning beds, in the 8 weeks prior to Screening.\n* eGFR \\\u003C 90 mL\u002Fmin\u002F1.73 m2, defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, at Screening.","ALL","18 Years","65 Years",{"count":55,"type":56},30,"ESTIMATED","INTERVENTIONAL",[59],"PHASE2","The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.\n\nThe main question this clinical trial aims to answer is:\n\n• Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo?\n\nResearchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo.\n\nTrial participants will:\n\n* Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks.\n* Visit the clinic 7 times for check-up and tests.",[62],"Non-Segmental Vitiligo","NOT_YET_RECRUITING","2026-06-24",{"date":66,"type":67},"2026-06-25","ACTUAL",{"date":69,"type":56},"2026-06",{"date":71,"type":56},"2027-07",{"name":5,"class":6}]